Citadel Advisors
REVBU

Citadel Advisors’s Revelation Biosciences, Inc. Unit REVBU Stock Holding History

Citadel Advisors’s Portfolio REVBU Stock Details REVBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-17,315
Closed -$3.46K – 16203
2022
Q4 		$3.46K Buy
+17,315
New +$5.33K ﹤0.01% 14209

Citadel Advisors's REVBU Position: Q1 2023 in Review

Citadel Advisors sold out of Revelation Biosciences, Inc. Unit (REVBU) in Q1 2023, closing a stake of 17,315 shares — an estimated $3.46K sold.

Citadel Advisors first reported a position in REVBU in Q4 2022 and held it in 1 quarter. The position peaked at $3.46K in Q4 2022. 0 funds tracked by Wall St. Rank hold REVBU as of Q1 2023.

  • Citadel Advisors reported no remaining Revelation Biosciences, Inc. Unit position as of Q1 2023 after selling out during the quarter.
  • Citadel Advisors sold 17,315 Revelation Biosciences, Inc. Unit shares in Q1 2023, an estimated $3.46K.
  • Citadel Advisors first reported a position in Revelation Biosciences, Inc. Unit in Q4 2022 and held it in 1 quarter.
  • Citadel Advisors's Revelation Biosciences, Inc. Unit position peaked at $3.46K in Q4 2022.
  • 0 funds tracked by Wall St. Rank held Revelation Biosciences, Inc. Unit as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.